Protocol: PK Bridging ELISA Detecting Total Drug Using Anti-Cetuximab Antibodies
Pharmacokinetic (PK) Bridging ELISA protocol detects total drug (free and partially bound): For use with Anti-Cetuximab Monoclonal Antibodies HCA220 and HCA228P
This method provides a procedure for carrying out a PK ELISA with Anti-Cetuximab Antibodies HCA220 (capture antibody) and HCA228P (detection antibody), and using cetuximab for the standard curve.
Anti-Cetuximab Antibody HCA220 is an inhibitory antibody. Anti-Cetuximab Antibody HCA228P is a non-inhibitory antibody that does not inhibit the binding of cetuximab to its target epidermal growth factor receptor (EGFR). This combination enables measurement of free and partially bound cetuximab, which is equivalent to total drug when trough serum levels are above 4 μg/ml. The method should always be used in conjunction with product and batch specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.
View all of our cetuximab antibodies
Payment methods we support: